ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESM..................*JBDM Ver 2.0.15 (20th of December) - 2999001/0202101123262071CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120220518W12022051172deBibliographieenBibliographyfrBibliographieEP15775880.6201509232017081020181114enenen201462054257 P20140923US201462076823 P20141107US201562136324 P20150320US2022051820222020180103201801202004082020152019091320200408AL20200408EE20200808IS20200923LU20200408LV20200408SM20220518202220C07K 16/28 20060101AFI20190724BHEP C07K 16/30 20060101ALI20190724BHEP A61K 47/68 20170101ALI20190724BHEP A61K 39/395 20060101ALI20190724BHEP A61K 45/06 20060101ALI20190724BHEP A61K 31/00 20060101ALI20190724BHEP A61K 31/553 20130101 LI20190527BHEP A61K2300/00 20130101 LI20190527BHEP A61K 39/3955 20130101 LI20190529BHEP A61K2300/00 20130101 LI20190529BHEP A61K 39/39558 20130101 LI20151210BHEP A61K2300/00 20130101 LI20151210BHEP A61K 31/4184 20130101 LI20190527BHEP A61K2300/00 20130101 LI20190527BHEP A61K 31/635 20130101 LI20190527BHEP A61K2300/00 20130101 LI20190527BHEP A61K 31/454 20130101 LI20190527BHEP A61K2300/00 20130101 LI20190527BHEP A61K 39/39558 20130101 LI20151210BHEP A61K 45/06 20130101 LI20151210BHEP C07K 16/2803 20130101 LI20160325BHEP C07K 16/2887 20130101 LI20151210BHEP C07K 16/3061 20130101 LI20151210BHEP A61K2039/54 20130101 LA20151210BHEP A61K2039/545 20130101 LA20151210BHEP C07K2317/24 20130101 LA20151210BHEP A61K 47/6889 20170801 LI20170802BHEP A61K 47/6803 20170801 LI20170802BHEP A61K 47/6849 20170801 LI20170802BHEP A61K 47/6867 20170801 LI20170802BHEP A61K2300/00 20130101 LA20180126BHEP A61K 31/454 20130101 LI20190527BHEP A61K 31/553 20130101 LI20190527BHEP A61K 31/635 20130101 LI20190527BHEP A61K 39/3955 20130101 LI20160324BHEP A61K 31/4184 20130101 FI20160324BHEP A61K2039/507 20130101 LA20160324BHEP A61P 35/00 20180101 LI20200327BHEP deVERFAHREN ZUR VERWENDUNG VON ANTI-CD79B-IMMUNKONJUGATENenMETHOD OF USING ANTI-CD79B IMMUNOCONJUGATESfrPROCÉDÉ D'UTILISATION D'IMMUNOCONJUGUÉS ANTI-CD79BFRANCK MORSCHHAUSER ET AL: "Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).", JOURNAL OF CLINICAL ONCOLOGY, vol. 32, no. 15-suppl, 20 May 2014 (2014-05-20), page 8519, XP055235812,MATHIAS J RUMMEL ET AL: "Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial", THE LANCET, vol. 381, no. 9873, 6 April 2013 (2013-04-06), pages 1203-1210, XP055235726, GB ISSN: 0140-6736, DOI: 10.1016/S0140-6736(12)61763-2MEHTA AMITKUMAR ET AL: "Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma", CURRENT ONCOLOGY REPORTS, CURRENT SCIENCE, GB, vol. 17, no. 9, 21 July 2015 (2015-07-21), pages 1-10, XP035527919, ISSN: 1523-3790, DOI: 10.1007/S11912-015-0466-9 [retrieved on 2015-07-21]20150195.4368991020200103POLSON, Andrewc/o Genentech Inc. 1 DNA WaySouth San Francisco, California 94080USYU, Shang-Fanc/o Genentech Inc. 1 DNA WaySouth San Francisco, California 94080USCHU, Yu-Wayec/o Genentech Inc. 1 DNA WaySouth San Francisco, California 94080USWENGER, Michaelc/o F. Hoffmann-La Roche AG Grenzacherstrasse 124CH-4070 BaselCHHIRATA, Jamie Harue1 DNA WaySouth San Francisco, CA 94080 ,USLU, Dan1 DNA WaySouth San Francisco, CA 94080USF. Hoffmann-La Roche AG101394150SJK/FP7309289Grenzacherstrasse 1244070 BaselCHMewburn Ellis LLP101783151Aurora Building CounterslipBristol BS1 6BXGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRBA20170925ME20170925US201505176020150923enWO201604921420160331201613